Conexeu (CNXU) CCO David Bogart Exercises 750,000 Warrants

What Happened

• David Robert Bogart, Chief Commercial Officer and Director of Conexeu Sciences Inc. (CNXU), exercised 750,000 performance warrants on September 25, 2026. The warrants have an exercise price of $0.001 each, so the cash cost was $750. The Form 4 also reports a corresponding derivative conversion/disposition entry for 750,000 shares on the same date.

Key Details

• Transaction date: September 25, 2026; Form 4 filed September 28, 2026 (appears timely).
• Acquisition: 750,000 shares acquired via exercise of performance warrants at $0.001 per share (total $750).
• Disposition entry: 750,000 derivative shares also reported as disposed (reported value $0); filing notes this as a derivative conversion.
• Shares owned after transaction: not specified in the provided filing details.
• Footnotes:
  • F1: Transaction is exempt from Section 16(b) short-swing liability under Rule 16b-6(b).
  • F2: Some holdings are held by 0865546 B.C. Ltd., over which the reporting person has sole voting/dispositive power.
  • F3: The Performance Warrants were granted June 5, 2025, exercise price $0.001, 5‑year term; 750,000 vested and exercised, 250,000 remain subject to vesting upon the issuer submitting a 510(k) to the FDA.

Context

• This was an exercise of performance warrants (a derivative-to-equity conversion) rather than an open-market purchase or sale. The filing shows both the exercise (acquisition) and a derivative conversion/disposition entry — typically reflecting conversion of warrant rights into common shares; the filing does not indicate an immediate open-market sale of the shares for cash.
• The remaining 250,000 performance warrants will vest only upon a future FDA 510(k) submission, per the filing. The Rule 16b-6(b) exemption means this transaction is treated as exempt from short-swing profit recovery under Section 16(b).